StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) stock

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.99+0.03 (+0.76%)

Close on Nov 18, 2026Market cap $320.02MP/E –Yield –

Atea Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Atea Pharmaceuticals's revenue for the twelve months ending Dec 31, 2021 was $351.37M. For fiscal 2021 it was $351.37M, up 622.5% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2021Dec 31, 2021$351.37M+622.5%
FY2020Dec 31, 2020$48.63M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2021Dec 31, 2021$192.18M–
Q3 FY2021Sep 30, 2021$32.81M–
Q2 FY2021Jun 30, 2021$60.39M–
Q1 FY2021Mar 31, 2021$65.99M–

More Atea Pharmaceuticals figures

See a number that looks wrong?